The Stablelab hand-held reader detects and quantifies the biomarker Serum Amyloid A (SAA), an acute phase protein produced by the liver that increases rapidly and dramatically in response to inflammation.
Zoetis says that by measuring SAA, vets can assess the severity of an infection more quickly, often before clinical symptoms start, and are able to monitor the horse’s response over the course of treatment.1
Zoetis vet Wendy Talbot said: “Zoetis is committed to providing vets and horse owners with the most effective health products to better predict, prevent, detect and treat equine disease.
“The Stablelab test kit enables convenient, off-site testing for quick and accurate detection of a reliable indicator of infection in horses.
“Point-of-care testing is one of the fastest-growing areas of diagnostics and this test is rapidly becoming a standard of care in equine practice. SAA testing will help vets to quickly determine an appropriate course of intervention, positively impacting case outcomes.”
For more information, visit: www.stablelab.com. To place an order, contact your Zoetis Account Manager or the Zoetis Technical Team on customersupportUK@zoetis.com or 0845 300 9084 (option 3).
Reference
Virbac has launched Marfloquin, a marbofloxacin-based antibiotic indicated for the treatment of multiple infectious diseases in cats and dogs.
Marfloquin is presented as a palatable, divisible tablet for once daily administration and is available in three tablet strengths:
Virbac Companion Animal Marketing Manager Simon Boulton MRCVS said: "Marbofloxacin is valued by practices for its efficacy in treating a wide range of skin, soft tissue, urinary tract and respiratory tract infections. The launch of Marfloquin gives them a cost-effective alternative and strengthens our existing antibiotic range, which includes Rilexine (cefalexin) and Enrox (enrofloxacin)."
For more information, contact your territory manager or call Virbac on 01359 243243
In 2009, Chiara (pictured right) was the first to be awarded by examination the title of European Veterinary Specialist in Oncology after completing a one-year small animal internship at the University of Glasgow and a three-year residency in internal medicine and oncology at the University of Edinburgh.
Alongside her clinical work, Chiara is an honorary lecturer at the University of Liverpool and a multi-lingual specialist consultant, writer and lecturer at events in the UK and Europe. Her focus is on postgraduate training in small animal oncology and internal medicine and online education of pet owners and animal carers. Chiara is a member of the general and oncology examination committees of the European College of Veterinary Internal Medicine (ECVIM).
She said: "My aim is to provide veterinarians and owners on a daily basis with the most up-to-date information on cancer diagnosis and treatment options so pets can spend more time with their families whilst protecting their quality of life and preventing suffering."
Samuela is a European Specialist in Veterinary Ophthalmology with a special interest in ocular pathology as well as corneal disease and surgery.
She said: "Working at Willows allows me to be part of a talented and passionate team, and a chance to become the best ophthalmologist I can. Willows offers a very high level of patient care, and working here gives me the opportunity for constant scientific and clinical development."
The webinar, which is presented by equine internal medicine specialist David Rendle from Rainbow Equine Hospital, challenges some of the current perceptions of worm control in horses and explains why veterinary surgeons need to engage more with horse owners on the topic to ensure a sustainable approach to parasite control.
Supported by Virbac, maker of Equimax and Eraquell horse wormers, the webinar is free to BEVA members at http://www.ebeva.org/webinar74.
Representatives from all sectors of the veterinary profession are encouraged to apply for the role, which is to represent veterinary surgeons in those regions to BVA Council and help shape the association's strategy and policy development.
Candidates are required to be based in the region they represent and to have time available to commit to gathering members’ views on key policy areas, representing those views at three meetings per year in London, and one elsewhere in the UK (attached to BVA Members’ Day). They will also need to meet members at local events where possible, and promote the good name and values of BVA. All of this work is supported by BVA headquarters.
The term of the BVA regional representative role is for three years. It suits motivated individuals who are interested in current issues affecting the profession. BVA pays your expenses and you’ll get free BVA membership for the duration of your term.
Daniella Dos Santos, President of the British Veterinary Association (pictured right), said: "BVA Council plays a key role in helping us to achieve our mission as the leading body representing, supporting and championing the whole UK veterinary profession. Our regional representatives are integral to that mission and to the activities of Council - contributing to effective horizon scanning on matters of veterinary policy and providing an informed steer to BVA’s Policy Committee.
"With an increasingly complex veterinary landscape, and wide range of issues and potential outcomes for animal health and welfare and the veterinary profession it’s essential that members have the best person to represent them at the highest level within BVA."
Emma Callaghan, BVA Scottish Branch regional representative and 2019 Bleby Cup winner, added: "I am currently in the middle of my first term on BVA Council and I would encourage anyone who is considering taking part to put themselves forward for election. This is a fantastic chance to represent the views of your region and to help BVA members to get their voices heard. I’m really enjoying my time as a regional representative - it’s been such a wonderful opportunity to meet a range of people from across the profession and to develop new skills outside my day-to-day role."
BVA members who are interested in becoming a representative for their area can apply before 9am on 16 December 2019 when nominations close. For more information or to submit your application, visit www.bva.co.uk/council/
Royal Canin highlights that obesity is one of the most common diseases that veterinary professionals face, and impacts patients' quality of life1, as well as their life expectancy2,3. Compliance is a common challenge in weight loss and even those that successfully reach their ideal weight frequently regain weight later. It therefore makes sense, says the company, to focus on prevention as well as long term management for obese cats and dogs.
Caroline Burke, Royal Canin UK Weight Management Specialist said: "Obesity is one of the most common diseases that vets and nurses see in practice, and this webinar is the latest in our programme of education around weight management. Vets and nurses will have the opportunity to learn about how they can help prevent, as well as manage obesity in practice, allowing them to truly make a difference to the lives of their patients."
Alex added: "Obesity is an ever-growing issue for cats and dogs, understanding the risks and prevention techniques is paramount for both pet owners and industry experts.
"This webinar aims to suggest how a lifelong practice monitoring programme can be implemented for the prevention of obesity. Whilst also reviewing the outcomes of weight management and defining types of prevention techniques which can be implemented."
To register for the webinar, 'How to be proactive rather than reactive for effective, preventative obesity management’, visit: https://vetportal.royalcanin.co.uk/cpd/webinar/
References
Intervet/Schering-Plough Animal Health has launched a new oxytetracycline spray which the company says offers more accurate antibiotic delivery whether the can is used in an upright or inverted position.
Alasdair King MRCVS, Intervet/Schering-Plough Animal Health veterinary manager, says new Engemycin Spray has been developed specifically to address problems reported with traditional aerosol cans:
"Antibiotic sprays are used widely, yet they can become a practical nuisance to both vets and farmers simply because many cans do not perform satisfactorily. All too frequently the nozzle leaks or detaches, the spray pattern is irregular - particularly if the can is held upside down as it so often needs to be - or the valve clogs before the can is empty. This can be a source of great frustration to users, but new Engemycin Spray overcomes all these problems."
Intervet/Schering Plough says Engemycin Spray combines a unique, quick-drying formulation with an innovative, non-clogging spray valve. The quick-drying formulation minimises wastage from the sprayed area, while the new valve - which works as well when the can is upside down - cuts spraying time and ensures more reliable and constant delivery of antibiotic. The valve is unique and designed to enable the can to fully empty.
Engemycin Spray is licensed for the treatment of foot and wound infections in cattle, sheep or pigs following surgery or physical injury. The new product is available now from wholesalers.
Agria Pet Insurance has announced the launch of a new campaign to highlight the threat to animals from everyday poisons and toxins.
As part of its campaign, the company is encouraging vets and nurses to help clients keep their pets safe by sharing knowledge about specific toxins - increasing awareness of substances which can cause harm.
To support vets in advising clients, Agria has produced a poster designed for in-practice display (pictured right, click to enlarge), covering some of the main threats to cats and dogs that owners may come across in their everyday lives. Dangers include: ingestion of antifreeze and paracetamol by cats, certain human foods and rock salt by dogs.
International Cat Care, currently running the campaign ‘Keeping Cats Safe’ in conjunction with Agria, feels that many poisonings could be prevented if only owners knew the risks.
Claire Bessant, from the charity, said “Accidental poisonings are heartbreaking because they are so often preventable - owners just weren’t aware of the dangers. Even worse, sometimes people are trying to help their animals - such as when owners give paracetamol, unaware that it can be lethal for cats.
"We’re delighted that Agria is helping reduce the risk of poisoning with this veterinary campaign and we encourage vets to do their bit and display a poster." To order a copy of Agria’s poster – ‘Responsible Pet Ownership Month – taking extra care of your pet!’– to display in your practice, email the Agria vet team at admin.vet@agriapet.co.uk, or call them on 03330 30 83 90.
Animalcare Ltd has launched Tilmodil (tilmicosin 300mg/ml solution for injection), a semi-synthetic macrolide antibiotic licensed for pneumonia in cattle and sheep, foul in the foot in cattle, and footrot and mastitis in sheep.
According to the company, Tilmicosin is fast-acting1, long-acting2 and highly effective against the major Gram-ve bovine respiratory pathogens.2,3 In addition, the company says tissue penetration is excellent.1 In calves a single SC injection at 10mg/kg bw results in lung concentrations exceeding the MIC90 of Mannheimia haemolytica for 72 hours.2
Animalcare says that pooled data from greater than 6000 cattle has confirmed the effectiveness of tilmicosin in the treatment of bovine respiratory disease (BRD) in well-controlled, randomised field studies. Tilmodil treatment has been proven equally effective compared to antibiotics, such as florfenicol, marbofloxacin and danofloxacin.
A recent report by the Farm Animal Welfare Council estimates that three million of the national sheep flock are lame at any one time. It is estimated that footrot is responsible for greater than 90% of lameness and is present in 97% of flocks. Tilmicosin has good activity against the key Gram-ve pathogens2 and has been successfully used in the treatment of footrot.4
Tilmodil has been developed for animal use only and is administered by veterinary surgeons only. Dosage is 1ml per 30kg bw for respiratory disease and mastitis in sheep and 0.5ml per 30kg bw for interdigital necrobacillosis (foul in the foot/footrot/bovine pododermatitis).
Tilmodil is administered as a single, low volume subcutaneous (SC) injection dose and presented in 50ml multi-dose vials.
1. Apley M., Antimicrobial therapy of Bovine Respiratory Disease.Veterinary Clinics of North America.Food Animal Practice (1997) 13,3:159-5622. Tilmodil SPC3. Giguere S et al .,Antimicrobial therapy in Veterinary Medicine.4th edition 2006.Chp.12,2014. Winter A., Lameness in sheep. 2. Treatment and control. In Practice (2004),3, 130-139.
Whilst the decision has been welcomed by the BVA and leading animal charities, it has not been entirely free of controversy. According to various reports, the Press Association has seen a letter from Defra to the Royal Veterinary College in February this year, which said the scientific studies it had commissioned were 'not strong enough to support a ban'.
Talking to the BBC, Ian Gregory, a lobbyist for pet collar manufacturers said that charities had also exaggerated the shock delivered by the collars, which at typically one millijoule is 1000 times less than cattle fencing. He argued that: "The anecdotal problems reported with pet collars can be resolved by product standards rather than by banning a proven technology".
The government has stopped short of banning invisible fencing systems which can keep pets away from roads, saying that the devices are particularly useful for cat owners and animals often respond well to invisible fencing and quickly learn to stay within a boundary without receiving a static pulse.
BVA President John Fishwick said: "As we review the latest evidence on the welfare impact of pulse pet containment fences, we would like to see them covered by a code of practice, as well as the regulation of the sale of these devices and manufacturer’s instructions, to ensure that the potential adverse effects of use are highlighted to animal owners and consumers."
Photo: Shutterstock
AceSedate for horses contains 10mg/ml acepromazine as its active ingredient, which the company says means a lower dose volume is required compared to the non-UK licensed equine acepromazine options available.
The dosage of AceSedate is 0.03-0.10 mg per kg bodyweight, however Jurox recommends that the lower end of the dose range is always selected where possible. It can be administered via intramuscular or slow intravenous injection.
AceSedate is supplied in a multidose vial and the shelf life after opening the immediate packaging is 28 days.
Richard Beckwith, country manager of Jurox (UK) Ltd, said: "The launch of AceSedate means injectable acepromazine is now licensed in the UK for horses, giving vets peace-of-mind that a licensed product is now available. It is a welcome addition to our equine anaesthesia, analgesia and sedation portfolio."
For more information, visit: www.jurox.com/uk, contact your local Jurox technical sales representative, telephone the customer services team on 0800 500 3171 or e-mail customerservice@jurox.co.uk.
The RCVS is inviting responses from veterinary surgeons, veterinary nurses and animal owners to a call for evidence on the provision of 24-hour emergency veterinary care, in order to understand how best to meet the expectations of all those involved.
In an open letter to the profession and the public published on the RCVS website, the Chairman of the RCVS Standards Committee, Clare Tapsfield-Wright, said:
"Over the past two years, lay people working with the RCVS have raised questions about the veterinary profession's ability to provide 24/7 to the extent required by the RCVS Code of Professional Conduct, and said there is a disconnect between the public's expectations and the profession's capacity to meet those expectations."
Clare also refers to an RCVS Disciplinary Committee Inquiry in June 2013, which raised a number of issues on home visits by veterinary surgeons, including: speed of response; travelling time and distance; daytime versus out-of-hours obligations; individual versus corporate responsibility; and, staffing levels and contingency plans.
The letter is accompanied by a range of background information, including the reports of Lay Observers to the RCVS Preliminary Investigation Committee; Working Party reports from the College's 2009 consultation on 24-hour emergency cover; and, further details about the June 2013 DC Inquiry.
The College says additional feedback will be sought through next year's RCVS Survey of the Professions, and via focus group research for animal owners. Once all responses have been collated, a number of individuals and organisations will be invited to a Standards Committee meeting to present and discuss their views.
Responses in writing are invited by 5pm on Monday, 17 February 2014, and should be emailed to 24-7@rcvs.org.uk or posted to the Professional Conduct Department, Royal College of Veterinary Surgeons, Belgravia House, 62-64 Horseferry Road, London SW1P 2AF.
RCVS CEO Lizzie Lockett said: "I am so proud of our performance in the Great Place to Work Awards and the efforts of everyone at the College, and especially our HR team, who have been tirelessly and creatively striving to make the College a wonderful place to work.
"Consistently being placed in the top 50 Great Places to Work is also a testament to the sustained hard work all of our employees and the important part they play in creating a supportive, interesting and good-humoured workplace.
"We are a service-led organisation and we want to make sure that we give our best to the veterinary professions and the general public. If our team enjoys the work, and the workplace, that will improve the service we are able to offer and, ultimately, benefit animal health and welfare."
Bovilis Bovivac S is used for active immunisation to induce serological and colostral antibody production against Salmonella Dublin and Salmonella Typhimurium.
In the face of an outbreak, it can also be used to reduce Salmonella Typhimurium infections when used as part of an overall herd management programme.
MSD says Bovilis Bovivac S may also contribute to reducing S. Typhimurium contamination of the environment. Other than the packaging, the vaccine itself is identical.
Patricia will take up the position at the start of November, replacing Mark Ross who is stepping down.
Patricia originally joined Vets Now in 2009, working in areas of hospital management and then business development.
She became COO in June 2021.
Patricia said today: “Vets Now is made up of fantastic people and it’s the honour of my career to be leading such a talented team.
“Our out-of-hours business model was set up twenty years ago by a vet to support the working practices of vets and vet nurses, helping to improve their work-life balance by providing outstanding animal care at times of greatest need to customers. As leaders in emergency care for small animals, we’ll continue to work steadfastly in supporting the profession.
“Mark has done a tremendous job driving the business forward and I’m excited to be able to continue to build on our success. “
Vets Now says it is working hard to drive diversity and inclusion within the profession, and with 88% of Vets Now staff being female, Patricia will lead a board of directors of whom nine out of ten are women.
That doesn't sound very diverse to me.
Where are the men?
The toolkit has been developed in conjunction with the RSPCA and includes a welfare workflow, quick download guides and welfare case forms. It can be downloaded here .
Merry Smith, a BEVA council member who led the project on behalf of BEVA, said: "Welfare assessments can sometimes be intimidating and it’s natural to feel vulnerable, particularly when circumstances are difficult. Our new Welfare Case Toolkit gives you access to the information and resources, even when you are on the road, to support you in dealing with a welfare case."
The interactive Welfare Workflow provides a step-by-step guide to what happens when a vet is called upon to provide an opinion on the health and welfare of the animals involved. It has been produced in a mobile-friendly format or can be printed out and kept in the car. Supporting the Workflow is a series of quick downloads, covering all aspects of the process:
Approach to the welfare case
Letter of instruction
Section 18 of the Animal Welfare Act (2006) certificate
Witness details sheet
Witness statement form
RSPCA vet exam form
Guidance notes on how to complete a vet exam welfare case form
Caroline Allen, Chief Veterinary Officer at the RSPCA said: "Vets are absolutely critical to the work of the RSPCA and while we know many vets get a lot of satisfaction from this work saving animals from cruelty and suffering, we know that this work can sometimes be daunting and the law confusing. We are delighted to have worked with BEVA on providing this guidance and hope it is the first step in us providing more support to vets doing this vital work- we literally couldn't do it without you"
The Welfare Case Toolkit is available free to BEVA members https://www.beva.org.uk/Resources-For-Vets-Practices/Clinical-Practice-Guidance/Welfare-guidance/Welfare-toolkit
Charcovet Gel contains 30g of activated charcoal in a 60ml syringe.
Dr John Henderson, Large Animal Product Manager at Forte Healthcare said: “In young animals with digestive disturbances, Charcovet Gel uses the adsorbent properties of activated charcoal to support the gut in a return to normal function.
"The value of using activated charcoal in cases of digestive upset in young animals has long been recognised, but the difficulty and mess involved in mixing such a fine dry powder in water presented considerable usability issues.
"With Charcovet Gel, the appropriate volume of activated charcoal gel is simply selected from the graduated syringe and administered directly into the animal’s mouth.
"Charcovet Gel can be given daily as needed to support the animal during the period of digestive upset.”
Each box of Charcovet Gel contains 12 syringes.
Charcovet Gel is available now from all major veterinary wholesalers, or directly from Forte Healthcare Ltd.
For more information contact your Forte Territory Manager, email enquiries@fortehealthcare.com or visit: https://www.fortehealthcare.com/product/charcovet-gel
Elanco Companion Animal Health has launched a novel prescription flea treatment for dogs which, according to the company, combines a rapid kill rate with convenient monthly oral administration.
Elanco says Comfortis Chewable Tablets for Dogs start to kill fleas within 30 minutes, providing 100 per cent control in four hours, the fastest specific claim of any approved flea preventive.
The product is based on a unique active ingredient, Spinosad, a naturally occurring fermentation product of soil bacteria with a unique insecticidal effect. Since its launch in the United States in 2007, Comfortis has established itself as the number one recommended prescription flea medication in that country and has now received European authorisation.
Elanco says the combination of its rapid action and oral method of administration is expected to prove particularly helpful in cases including:
Jannes Nijland, marketing and innovation director for Elanco Companion Animal Health in Western Europe, said: "The veterinary profession has indicated a strong desire for a prescription only flea treatment. While vets remain the 'first port of call' for advice on flea medication, our research shows that only 42 per cent of dog owners still buy their treatments from practices. We believe that the launch of an alternative approach to flea control available from practices could help vets strengthen their client relationships."
He added: "Comfortis is the first product developed and launched by Elanco Companion Animal Health in Western Europe. It is a perfect demonstration of how we intend to deliver on our mission to help veterinarians help pets live longer, healthier and higher quality lives."
For further information about Comfortis, veterinary practices should contact their Elanco key account manager, or to contact the company directly on 01256 779881
Additional information about Elanco is available at www.elanco.com and the company can be contacted via email at elancoCAH.uk@lilly.com
A free copy of the compendium has been sent to every veterinary practice in the UK, and it is also available online at: www.noahcompendium.co.uk. A special edition of the book commissioned by AMTRA will also be available for its SQPs shortly.
NOAH chief executive Dawn Howard said: "The NOAH Compendium, in all its formats, remains a major part of NOAH’s efforts to ensure appropriate access and responsible use of medicines for all animals. We are pleased it is even more comprehensive this year, as we continue to expand its list of contributors.
"Every NOAH member, as well as the non-member participants in the NOAH Compendium, is a signatory to the NOAH Code of Practice on Promotion, which demonstrates their commitment to operate above and beyond any regulatory requirements."
She added: “As well as product datasheets, the Compendium includes another vital resource – the contact details for each participating company. Company veterinary and technical advisors have detailed knowledge about their company’s medicines. The NOAH Code includes the requirement for NCAH qualification for NOAH staff in technical dialogue with prescribers and users of animal medicines – meaning their advice can be regarded as a valuable and trusted resource. They are ready to talk to prescribers about the use of a medicine in a particular animal or in a particular situation, as well as to explain any queries about the data sheet."
Veterinary practices that have not yet received a copy, perhaps because they are new or have changed address in the past year should contact NOAH (noah@noah.co.uk).
Extra copies are also available to order, for £47.50. Special prices are also available for bulk orders.
Meanwhile, the BVA has published the results of its latest Voice of the Profession survey which found that 99% of vets have seen pets in the last 12 months which should have been brought to them for treatment earlier, with 91% reporting that financial reasons were the main factor.
52% of vets also said the number of clients reporting difficulty covering the cost of preventative veterinary care for their animal had increased compared to 2021.
This figure rose to 70% when it came to covering the cost of diagnostic care and treatment.
The Dogs Trust survey, which was carried out by YouGov, asked owners how easy or difficult they would find it to pay vet bills of varying amounts.
10% of pet owners said they would find it fairly difficult to pay unexpected vet bill of £100.
5% said they would find it very difficult.
Overall, 13% said they either cannot afford, or are struggling to afford, the costs of owning a dog in the current climate.
Meanwhile, the charity reports it is getting record numbers of owners asking to hand over their dogs: an average 188 handover requests per day in February compared to an average 141 handover requests per day in 2022, which was itself a record-breaking year (ending in over 50,000 rehoming requests).
In response, Dogs Trust has set up dog food banks at some of its rehoming centres across the UK, which are open to anyone struggling to feed their dog.
The charity has also started a petition asking the Chancellor to Paws the VAT on pet food and veterinary services: https://www.dogstrust.org.uk/support-us/campaigns-appeals/cut-vat-petition
When pet owners were asked in the YouGov survey to what extent they would support or oppose the Chancellor removing VAT from vet care and pet food in next Wednesday’s budget, 61% said they would support it, with 36% of those saying they would strongly support it.
Discuss the value, or not of diagnostics here: https://www.vetsurgeon.org/001/nonclinical/f/life-in-practice-discussions/30519/the-value-or-not-of-diagnostics
www.dogstrust.org.uk
The consultation, which was held by the College early in 2017, asked for the views of veterinary surgeons and nurses, animal owners, and stakeholders on the use of telemedicine in veterinary clinical practice.
The consultation was designed to help identify potential risks associated with telemedicine, identify areas where it may help address the needs of both clinicians and the public, and support the potential development of new professional standards and guidance.
The online survey of veterinary professionals received 1,230 responses, while the public consultation received 229 responses and the survey of organisations/stakeholders received eight responses.
The headline question asked of veterinary professionals was whether RCVS 'supporting guidance to the Code of Professional Conduct' should be amended to allow remote examination to take the place of physical examination in certain circumstances. 41% said 'Yes', 40% said 'No' and 18% were unsure.
Veterinary professionals and organisations were then asked a series of questions in order to establish how they rated the risk associated with telemedicine according to activity type, practice type, clinical sign or syndrome, mode of technology, and familiarity with client, animal or environment.
Unsurprisingly perhaps, the majority felt that providing just general advice presented a low risk. At the other end of the scale, most felt that the use of telemedicine to diagnose disease or injury would be either 'high risk', or 'not appropriate at all'.
Likewise, the majority said the risks would be low or medium where the client and environment were known and the animal seen before, for the same problem. By contrast, the majority said telemedicine would be either 'high risk' or 'not appropriate at all' when the client, animal and environment were all unknown.
When asked whether the current definition of 'under care' should be extended to allow veterinary surgeons to prescribe veterinary medicines where there has been no physical examination of the animal, 69% said 'No', 16% said 'Yes' and 15% were unsure.
However, when asked whether certain types of veterinary medicines should be able to be prescribed without a physical examination of the animal, the majority of respondents to the professional survey (52%) were in favour.
The results of the consultation were first considered at a special meeting of the Standards Committee in August 2017, where it was noted how the consultation had revealed significant confusion around current supporting guidance to the RCVS Code of Professional Conduct and that, at a minimum, clarification as to what was currently permissible was needed.
The Committee determined a key issue going forward was whether to change the Supporting Guidance to the RCVS Code of Professional Conduct regarding 'under care' to allow veterinary surgeons to prescribe POM-V medicines based on telemedicine alone.
Given the complex nature of the issues and the wide-ranging implications, the Standards Committee presented a range of options for amending RCVS Guidance to RCVS Council at its meeting in November 2017. After discussion, Council asked the Standards Committee to continue their review and to present more detailed proposals to Council regarding the future of telemedicine in clinical veterinary practice.
Anthony Roberts, RCVS Director of Leadership and Innovation, said: "We would like to thank all those who took the time to respond to the consultation – although Council has not yet made any firm decisions, we felt it would be useful to share our research so far.
"The use of telemedicine is growing rapidly in human healthcare and it is only right the RCVS assesses the opportunities it could bring to improve access to veterinary services. It is critical, however, that we understand the issues it presents 'at the coal face' and consider all the available evidence before making any changes to our Guidance. The RCVS should ensure its regulatory framework fosters innovation and maximises the opportunities to improve the quality, efficacy and accessibility of veterinary services, whilst at the same time protecting animal health and welfare."
The Standards Committee will meet again in April 2018 to take further evidence and develop proposals to take the issue forward.
Meanwhile, the full summary is available on the College’s website: www.rcvs.org.uk/telemeds-summary/.
The Ear Protector sits on the back of the head and hooks onto face mask strings, pulling them backwards and away from the ears, thereby relieving pressure and stopping chafing.
The product was designed by AMufacture's Chief Operating Officer, William Howden, a former Olympic sailor who competed in the 2008 Summer Olympics in Beijing. He said: "Early in the pandemic, it became apparent to us that there was a serious need to address an unresolved problem with face masks – people were really beginning to suffer and were getting distracted from their work."
The Ear Protector is sterilisable in a dishwasher. It is also recyclable when it reaches the end of its life.
The Ear Protectors cost fifty pence each, for orders of two hundred. Contact the company direct for lower volume pricing.
For more information, visit: http://www.theearprotector.com
Ceva Animal Health has renamed Tildren, its tiludronate-based bisphosphonate infusion for the treatment of bone spavin in horses, as Equidronate.
Tiludronate has been used to treat bone spavin and navicular disease in Europe for many years and was licensed for bone spavin in the UK in 2008. Ceva says trials published last year show that horses suffering lameness caused by bone spavin can show marked improvement following treatment with an Equidronate infusion, in combination with controlled exercise.
Bone spavin is a chronic aseptic osteoarthritis of the distal tarsal joints and is considered to be one of the most common forms of hindlimb lameness in the horse. Horses with bone spavin experience abnormal bone remodeling changes. According to the company, Equidronate helps to modulate the osteoclasts to help prevent excessive bone removal and give the osteoblasts a chance to catch up. This in combination with adjusting levels of exercise helps to harmonise the bone adaptation needed for the horse to perform its athletic duties.
In the trials one in four horses showed marked improvement; two in four showed improvement, which, when combined with other treatment, enabled the horse to resume former levels of activity and one in four horses showed no response.
Ceva Animal Health has produced a range of explanatory leaflets for horse owners on bone spavin, navicular disease and sacroiliac disease, as well as a helpful booklet detailing the discharge procedures for horses that have been treated with Equidronate.
For free copies and for further product information contact your Ceva sales representative, ring Ceva on 01494 781510 or visit the website at http://www.ceva.uk.com/
Instead of conducting major open surgery, Chris Shales, an RCVS and European Specialist in Small Animal Surgery, Andrew Kent, a European Specialist in Internal Medicine, and the cardiology team at Willows are using coil embolization, a minimally invasive technique which they say is far safer and less likely to lead to post-operative complications.
The procedure involves threading tiny coils, via the jugular vein, through the venous system and positioning them in the blood vessel that needs to be closed. The coils encourage the blood to form a clot and so, over time, seal the vein.
Chris said: "This procedure of treating intrahepatic portosystemic shunts is associated with a lower risk of mortality and a lower surgical morbidity rate when comparted to open surgery. The overall outcome of the two approaches is similar in terms of reduction of flow through the shunt vessel.
"Access is gained via a small incision in the neck to allow the team to operate on the liver via the jugular vein using fluoroscopy to visualise the placement of a stent within the vena cava and embolization coils within the abnormal vessel.
"Intrahepatic shunts can be extremely challenging for the surgical team to access with the result that standard, open surgical treatment of these abnormal vessels can risk life-threatening complications and animals can require a significant time to recover."
For more information about shunt surgery at Willows, contact Chris Shales or Small Animal Internal Medicine Specialist Andrew Kent on 0121 712 7070 or email enquiries@willows.uk.net.
Photo: Chris Shales, left, with Andrew Kent, centre, and cardiologist Mike Martin ('pass me a gin and tonic, would you').
Running in July, the campaign aims to raise awareness of hyperthyroidism in cats and hypothyroidism in dogs, educate pet owners to spot the symptoms and thereby encourage early diagnosis.
MSD Animal Health says it hopes the campaign will increase the number of pets being taken to their veterinary practice for diagnosis, and increase both return visits and treatment compliance.
Practices supporting Pet Thyroid Month will be supplied with resources to help them educate pet owners about the two conditions.
Caroline Darouj, product manager at MSD Animal Health, said: "Although hyperthyroidism in cats and hypothyroidism in dogs are well known conditions and diagnosis is generally straightforward, a large number of vets in Europe state that both disorders are under-diagnosed, due to the fact that pet owners don’t recognise the signs.
"We wanted to launch our Thyroid Month campaign to encourage pet owners to spot the early symptoms of thyroid issues in their pets and seek advice from their veterinary practices.
"Our aim is also to benefit and educate vets and vet nurses with regard to the use of Leventa and Vidalta in treating these manageable conditions in both dogs and cats."
To find out more about Pet Thyroid Month, visit www.vidalta.co.uk